Market Overview - The Shanghai Composite Index closed at 3869.25 points, with a change of 0.10% [1] - The total trading volume of A-shares reached 1,280.495 billion yuan [1] Technical Analysis - A total of 175 A-shares experienced a death cross between the 5-day and 10-day moving averages [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Yuanjie Technology: 5-day MA down by 2.50% from the 10-day MA [1] - Shanshan Shares: 5-day MA down by 2.32% from the 10-day MA [1] - Zijian Electronics: 5-day MA down by 2.09% from the 10-day MA [1] Individual Stock Performance - Yuanjie Technology (688498): Increased by 3.59% with a trading turnover of 2.90% [1] - Shanshan Shares (600884): Increased by 0.22% with a trading turnover of 3.13% [1] - Zijian Electronics (301121): Decreased by 0.60% with a trading turnover of 3.19% [1] - Other notable stocks include: - WuXi AppTec (603259): Increased by 2.21% [1] - Fabon (300925): Increased by 1.67% [1] Summary of Stocks with Death Cross - Stocks with a death cross and their respective metrics include: - Yuanjie Technology: 5-day MA at 374.57 yuan, 10-day MA at 384.17 yuan [1] - Shanshan Shares: 5-day MA at 14.17 yuan, 10-day MA at 14.51 yuan [1] - Zijian Electronics: 5-day MA at 48.72 yuan, 10-day MA at 49.76 yuan [1] - The latest prices of these stocks are below their 10-day moving averages, indicating potential bearish trends [1]

Core Points - The Shanghai Composite Index is at 3876.54 points with a change of 0.29%, and the total trading volume of A-shares is 961.216 billion yuan [1] - A total of 158 A-shares have seen their 5-day moving average cross below the 10-day moving average, indicating potential bearish trends [1] Group 1: Stocks with Significant Moving Average Crosses - Yuanjie Technology (688498) has a 5-day moving average of 374.30 yuan, which is 2.53% lower than its 10-day moving average of 384.03 yuan, with a current price of 357.58 yuan, down 6.89% from the 10-day average [1] - Shanshan Co., Ltd. (600884) shows a 5-day moving average of 14.14 yuan, down 2.43% from its 10-day moving average of 14.49 yuan, with a current price of 13.29 yuan, down 8.28% from the 10-day average [1] - ZhiJian Electronics (301121) has a 5-day moving average of 48.75 yuan, which is 2.05% lower than its 10-day moving average of 49.78 yuan, with a current price of 46.54 yuan, down 6.50% from the 10-day average [1] Group 2: Other Notable Stocks - WuXi AppTec (603259) has a 5-day moving average of 102.27 yuan, which is 1.97% lower than its 10-day moving average of 104.33 yuan, with a current price of 98.12 yuan, down 5.95% from the 10-day average [1] - Fabon Information (300925) shows a 5-day moving average of 25.73 yuan, down 1.78% from its 10-day moving average of 26.20 yuan, with a current price of 25.13 yuan, down 4.07% from the 10-day average [1] - Loka (603829) has a 5-day moving average of 21.29 yuan, which is 1.73% lower than its 10-day moving average of 21.67 yuan, with a current price of 20.07 yuan, down 7.37% from the 10-day average [1]

Core Viewpoint - The company is actively developing the Hainan Decheng International Medical and Health Complex project, leveraging the Hainan Free Trade Port's "medical special zone" policy to create a high-end integrated health industry model [1] Group 1: Project Development - The company has a subsidiary in Chengmai County, Hainan Province, which is responsible for the construction of the international medical and health complex [1] - The project is positioned as an international medical and health complex, relying on a secondary rehabilitation hospital and targeting health, vacation, and recuperation clientele from Chengmai and Haikou, with a nationwide reach [1] - Some main structural components of the project have already been capped, and the construction of other structural elements is progressing steadily [1] Group 2: Future Plans - The company plans to fully utilize global high-quality medical resources and actively explore potential development opportunities in Hainan [1] - The goal is to establish the complex as a high-end integrated facility centered around a "high-end international hospital," achieving an integrated high-end ecological closed-loop health industry model that encompasses "medical care, research, travel, and tourism" [1]

Core Viewpoint - The report highlights the growth of industrial enterprises in the Xinjiang Uygur Autonomous Region, indicating a significant increase in the number of large-scale industrial companies, which presents potential investment opportunities in the region's industrial sector [1] Group 1: Company Information - Listed companies mentioned include Guanghui Energy, New Natural Gas, Unified Shares, ST Haoyuan, Xinjiang Torch, Western Animal Husbandry, Tianrun Dairy, Dezhan Health, Xuefeng Technology, Chuaning Biological, Xiling Information, Lide New Energy, and Tianfu Energy [1] - The report is published by Zhiyan Consulting, a leading industry consulting firm in China, specializing in deep industry research and providing comprehensive consulting services [1] Group 2: Industry Statistics - As of January to August 2025, the number of industrial enterprises in Xinjiang reached 5,415, an increase of 477 compared to the same period last year, representing a year-on-year growth of 9.66% [1] - The industrial enterprises in Xinjiang account for 1.04% of the total number of such enterprises in the country [1] - The threshold for large-scale industrial enterprises was raised from an annual main business income of 5 million yuan to 20 million yuan starting in 2011 [1]

Core Viewpoint - The company Dezheng Health (000813) announced that its associate company Dongfang Lue has completed patient enrollment for the Phase III clinical trial of its key product VGX-3100, which is aimed at treating high-grade cervical precancerous lesions associated with HPV-16 and/or HPV-18 [1] Group 1 - The Phase III clinical trial for VGX-3100 has completed all patient enrollments [1] - Two additional indications for treating high-grade anal and vaginal precancerous lesions associated with HPV-16 and/or HPV-18 have received approval from the National Medical Products Administration, allowing them to proceed directly to Phase II clinical trials [1]

证券日报网讯德展健康（000813）9月29日在互动平台回答投资者提问时表示，公司在研创新药涵盖化 药及生物药领域，包括化药领域重点在研1类创新药脑神经保护剂WYY、抗血栓药物ZT等，生物药领 域重点在研2类创新药CBD治疗罕见病肺动脉高压等，各项目均按计划有序推进中，其中WYY注射液脑 卒中适应症IND申报相关实验基本完成，预计下半年提交临床试验申请，同时推进舌下片剂型研究及新 适应症探索性研究；ZT项目候选药物基本确定；CBD治疗罕见病肺动脉高压项目已启动大麻二酚原料 药DMF备案筹备工作。参股公司东方略在研重点产品VGX-3100的首个适应症(用于HPV-16和/或HPV-18 相关的宫颈高级别癌前病变的治疗)Ⅲ期临床试验已完成全部患者入组。用于HPV-16和/或HPV-18相关 的肛门高级别癌前病变和阴道高级别癌前病变治疗的两个适应症已取得国家药监局的批复，直接进入临 床II期试验。有关在研项目、参股公司、股东人数等详情请见公司定期报告。 ...

Core Viewpoint - The company, Dezhan Health (000813), emphasizes its commitment to focusing on its core business and enhancing its operational management to improve core competitiveness and intrinsic value, aiming to better reward investors' trust and support [1] Group 1 - The company will continue to concentrate on its main business operations [1] - The company aims to solidify its operational management practices [1] - The company is dedicated to enhancing its core competitiveness and intrinsic value [1]

Core Viewpoint - The company, Dezhan Health (000813), is actively engaged in multiple self-developed innovative drug projects at various stages of research and development, while also exploring collaboration opportunities [1] Group 1 - The company emphasizes strengthening its independent research and development efforts [1] - The company is open to exploring cooperative opportunities in the pharmaceutical sector [1] - The company commits to adhering to information disclosure rules for any matters that require disclosure [1]

证券日报网讯德展健康（000813）9月29日在互动平台回答投资者提问时表示，WYY注射液脑卒中适应 症IND申报相关实验基本完成，预计下半年提交临床试验申请。 ...

格隆汇9月29日丨德展健康(000813.SZ)在投资者互动平台表示，WYY注射液脑卒中适应症IND申报相关 实验基本完成，预计下半年提交临床试验申请。 ...